1. Scrip
  2. >>Business
  3. >>Deals

Gilead Opts In On Multiple Arcus IO Candidates, Setting Up Combo Therapy Plans

 
• By Joseph Haas

Gilead is licensing two anti-TIGIT candidates and a pair of adenosine pathway-targeted drugs. The firms will study various IO combo regimens, possibly including Gilead drugs like Trodelvy.

Instagram style filter silhouette of a successful woman or girl arms raised celebrating at sunrise or sunset in front of the New York City Skyline
Arcus gets validation with Gilead opting in early on multiple IO candidates

Gilead Sciences, Inc. has elected to take three options under its May 2020 immuno-oncology collaboration with Arcus Biosciences, Inc., updating the deal in a way that will bring Arcus $725m in option fees and give Gilead the ability to explore multiple IO combinations, including ones that may include its own drugs and investigational candidates, such as its breast cancer therapy Trodelvy (sacituzumab govitecan).

“The early options by Gilead also enable us to access and benefit from the clinical, commercial and global resources of a much larger partner,” Arcus CEO Terry Rosen told an...

More from Deals

Deal Watch: QurAlis Targets Fragile-X Syndrome In Deals With Quiver, UMass

 
• By Joseph Haas

Plus the end of Sanofi’s six-target alliance with IGM, OmniAb’s deals with Veraxa and Angelini, alliances involving Skye/Arecor, Genprex/UTHealth Houston and more.

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

Genentech, Orionis Stick Together In Second Molecular Glue Deal

 
• By Alaric DeArment

Deal Snapshot: Orionis and Genentech signed a new partnership focused on molecular glues, on top of the one that they struck in 2023.

More from Business

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.

Finance Watch: SV Closes Second Dementia Discovery Fund, Exceeding $250m Goal

 
• By Mandy Jackson

Private Company Edition: SV Health Investors revealed the final closing of its second Dementia Discovery Fund. Also, Eikon cut nearly 15% of its staff, Pathos AI raised $365m in series D venture capital and CellCentric completed a $120m series C round, among other financings.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.